

LIFE SAVING DRUGS PROGRAM EXPERT PANEL

23rd MEETING: 13 MARCH 2026

AGENDA

1. Standing business

- 1.1 Welcome, apologies and Conflicts of Interest
- 1.2 Update on actions from previous meetings
- 1.3 Correspondence
- 1.4 Report from the Secretariat

2. Other business

- 2.1 Update to the LSDP Expert Panel on its referrals to the Pharmaceutical Benefits Advisory Committee (PBAC) of medicines for the treatment of Gaucher disease type 1 and hereditary tyrosinaemia type 1 that were considered by the PBAC at its [November 2025 meeting](#).
- 2.2 Consideration of Medical Services Advisory Committee advice on newborn bloodspot screening for mucopolysaccharidosis types I and II and its recommendations to review the eligibility criteria for treatment with medicines funded under the LSDP.

Note: There are no applications for new listings being discussed at this meeting.